Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHM 702- SLE, Gout, OA, RA > RA- Non-TNFi Biologics DI > Flashcards

RA- Non-TNFi Biologics DI Flashcards

1
Q

SQ non-TNFi biologics

A

Abatacept (Orencia)
Sarilumab (Kevzara)
Tocilizumab (Actemra)
Anakinra (Kineret)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Orencia MoA

A

Targets T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Kevzara MoA

A

Targets IL-6 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Actemra MoA

A

Targets IL-6 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Kineret MoA

A

Targets IL-1 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When are non-TNFi biologics used in RA treatment?

A

Used as monotherapy or with a non-biologic DMARD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Orencia SQ dosing

A

125mg QW

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Kevzara SQ dosing

A

200mg q2w

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Actemra SQ dosing

A

<100kg: 162mg SQ QOW, increase to QW as tolerated
≥100kg: 162mg SQ QW

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Kineret SQ dosing

A

100mg QD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Orencia ADEs

A

URTI
HA
Nasopharyngitis
Nausea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Kevzara ADEs

A

URTI
UTI
Injection site erythema
Neutropenia
Increased LFTs
Antibody formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Actemra ADEs

A

URTI
Nasopharyngitis
HA
HTN
Increased LFTs
Increased lipids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Kineret ADEs

A

URTI
Rash
Pyrexia
Influenza-like illness
Gastroenteritis
Vomiting
Antibody formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What should you screen for before starting a non-TNFI biologic?

A

Latent TB and Hep B infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Orencia monitoring

A

Monitor CBC at baseline and periodically throughout treatment

17
Q

Kevzara and Actemra monitoring

A

Monitor ANC, CBC, LFTs, FLP at baseline

Monitor CBC, LFTs, FLP after 4-8 weeks

Monitor CBC and LFTs q3months

Monitor FLP q6months

18
Q

Kineret monitoring

A

Monitor CBC at baseline and then q3months

19
Q

IV non-TNFi biologics

A

Abatecept (Orencia)
Rituximab (Rituxan)
Tocilizumab (Actemra)

20
Q

Rituximab MoA

A

Targets anti-CD20 antibody

21
Q

Orencia IV dosing

A

Weight-based dosing at 0, 2, and 4 weeks, then q4w

22
Q

Rituximab IV dosing

A

1g at 0 and 2 weeks (one cycle)

May repeat cycle q16-24wks based on response

23
Q

Actemra dosing

A

4mg/kg q4w followed by an increase to 8mg/kg q4w based on response

24
Q

IV Orencia ADEs

A

Same as SQ, but with HTN and infusion reactions too

25
Q

Rituximab ADEs

A

URTI
UTI
Nasopharyngitis
PML
Infusion reactions (premedicate with antihistamine, APAP, corticosteroids)

26
Q

Actemra IV ADEs

A

Same as SQ, but also infusions site reactions

27
Q

When to use rituximab in RA treatment guidelines

A

For patients who fail other bDMARDs or with a history of lymphoproliferative disorder

28
Q

Rituximab has to be taken with what drug?

29
Q

Adequate trial of non-TNFi biologic

PHM 702- SLE, Gout, OA, RA (36 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions